Pfizer's Trading Volume Drops 39.13% to $650 Million Ranking 165th in Market Activity

On July 24, 2025, Pfizer's trading volume was $650 million, a significant decrease of 39.13% from the previous day, ranking 165th in the day's stock market activity. Pfizer's stock price fell by 0.04%.

Pfizer has announced that it will be conducting a clinical trial for a new drug aimed at treating a rare genetic disorder. The trial, which is expected to begin in the fourth quarter of this year, will involve 500 patients across multiple countries. The company has expressed optimism about the drug's potential to improve the quality of life for patients suffering from this condition.

In other news, Pfizer has also revealed plans to expand its manufacturing capabilities in Europe. The company will invest $500 million in a new facility in Germany, which is expected to create 300 new jobs. This expansion is part of Pfizer's broader strategy to increase its presence in the European market and better serve its customers in the region.

Additionally, Pfizer has announced that it will be partnering with a leading biotechnology company to develop a new vaccine for a viral infection that has been on the rise in recent years. The partnership, which is expected to last for five years, will focus on conducting clinical trials and bringing the vaccine to market as quickly as possible. This collaboration is seen as a significant step forward in the fight against this viral infection.